caa a22 4500 605490619 CHVBK 20210128100505.0 cr unu---uuuuu 210128e20151201xx s 000 0 eng 10.1007/s10147-015-0831-6 doi (NATIONALLICENCE)springer-10.1007/s10147-015-0831-6 Prospective evaluation of the safety of transrectal ultrasound-guided transperineal prostate biopsy based on adverse events [Elektronische Daten] [Takeshi Namekawa, Satoshi Fukasawa, Atsushi Komaru, Masayuki Kobayashi, Yusuke Imamura, Takayuki Ohzeki, Kimiaki Takagi, Yosuke Sato, Koichiro Akakura, Tomohiko Ichikawa, Takeshi Ueda] Background: Although transperineal (TP) prostate biopsy is growing in popularity, its safety has not been evaluated based on extensive studies. We prospectively assessed the adverse events associated with transrectal ultrasound (TRUS)-guided TP 16-core prostate biopsy at a single institution. Patients and methods: We enrolled 2,086 males who underwent first-time TRUS-guided TP prostate biopsy under lumbar spinal anesthesia at Chiba Cancer Center between 2009 and 2013. Eight adverse events were assessed prospectively using a purpose-designed questionnaire. The prevalence and duration of all adverse events were evaluated. We performed subgroup analyses for hematuria and urinary retention in relation to clinical factors. Results: Questionnaires were collected from 1,663 cases (79.7%). The cancer detection rate was 53.5% in all patients. The prevalence and duration of complications were as follows: hematuria, 73.4% and 4.51±2.88days; perineal bleeding, 7.1% and 2.20±2.24days; hematospermia 14.4%; dysuria, 15.7% and 3.12±2.71days; urinary tract pain, 49.5% and 2.43±2.08days; perineal pain, 35.5% and 3.53±2.59days; fever ≥37°C, 1.7% and 1.79±1.72days; and headache, 22.1% and 3.40±2.10days. Seventeen patients (1.1%) required indwelling urethral catheterization for grade 2 urinary retention. Pre-biopsy International Prostate Symptom Score (p=0.014) was an independent related factor for hematuria. Prostate volume (p=0.001) was an independent related factor for grade 2 urinary retention. Conclusions: TRUS-guided TP prostate biopsy under lumbar spinal anesthesia can be performed safely with only minor adverse events. Japan Society of Clinical Oncology, 2015 Adverse events nationallicence Prostate cancer nationallicence Transperineal biopsy nationallicence Questionnaire nationallicence Namekawa Takeshi Prostate Center and Division of Urology, Chiba Cancer Center, 666-2 Nitona-cho, Chuo-ku, 260-8717, Chiba, Chiba, Japan aut Fukasawa Satoshi Prostate Center and Division of Urology, Chiba Cancer Center, 666-2 Nitona-cho, Chuo-ku, 260-8717, Chiba, Chiba, Japan aut Komaru Atsushi Prostate Center and Division of Urology, Chiba Cancer Center, 666-2 Nitona-cho, Chuo-ku, 260-8717, Chiba, Chiba, Japan aut Kobayashi Masayuki Prostate Center and Division of Urology, Chiba Cancer Center, 666-2 Nitona-cho, Chuo-ku, 260-8717, Chiba, Chiba, Japan aut Imamura Yusuke Prostate Center and Division of Urology, Chiba Cancer Center, 666-2 Nitona-cho, Chuo-ku, 260-8717, Chiba, Chiba, Japan aut Ohzeki Takayuki Prostate Center and Division of Urology, Chiba Cancer Center, 666-2 Nitona-cho, Chuo-ku, 260-8717, Chiba, Chiba, Japan aut Takagi Kimiaki Prostate Center and Division of Urology, Chiba Cancer Center, 666-2 Nitona-cho, Chuo-ku, 260-8717, Chiba, Chiba, Japan aut Sato Yosuke Prostate Center and Division of Urology, Chiba Cancer Center, 666-2 Nitona-cho, Chuo-ku, 260-8717, Chiba, Chiba, Japan aut Akakura Koichiro Division of Urology, Japan Community Health Care Organization, Tokyo Shinjuku Medical Center, Tokyo, Japan aut Ichikawa Tomohiko Department of Urology, Graduate School of Medicine, Chiba University, 1-8-1 Inohana-cho, Chuo-ku, 260-8670, Chiba, Japan aut Ueda Takeshi Prostate Center and Division of Urology, Chiba Cancer Center, 666-2 Nitona-cho, Chuo-ku, 260-8717, Chiba, Chiba, Japan aut International Journal of Clinical Oncology Springer Japan 20/6(2015-12-01), 1185-1191 1341-9625 20:6<1185 2015 20 10147 https://doi.org/10.1007/s10147-015-0831-6 text/html Onlinezugriff via DOI BK010053 XK010053 XK010000 Metadata rights reserved Springer special CC-BY-NC licence nationallicence 1 research-article jats NATIONALLICENCE NATIONALLICENCE NL-springer NATIONALLICENCE 856 40 https://doi.org/10.1007/s10147-015-0831-6 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Namekawa Takeshi Prostate Center and Division of Urology, Chiba Cancer Center, 666-2 Nitona-cho, Chuo-ku, 260-8717, Chiba, Chiba, Japan aut NATIONALLICENCE 700 1- Fukasawa Satoshi Prostate Center and Division of Urology, Chiba Cancer Center, 666-2 Nitona-cho, Chuo-ku, 260-8717, Chiba, Chiba, Japan aut NATIONALLICENCE 700 1- Komaru Atsushi Prostate Center and Division of Urology, Chiba Cancer Center, 666-2 Nitona-cho, Chuo-ku, 260-8717, Chiba, Chiba, Japan aut NATIONALLICENCE 700 1- Kobayashi Masayuki Prostate Center and Division of Urology, Chiba Cancer Center, 666-2 Nitona-cho, Chuo-ku, 260-8717, Chiba, Chiba, Japan aut NATIONALLICENCE 700 1- Imamura Yusuke Prostate Center and Division of Urology, Chiba Cancer Center, 666-2 Nitona-cho, Chuo-ku, 260-8717, Chiba, Chiba, Japan aut NATIONALLICENCE 700 1- Ohzeki Takayuki Prostate Center and Division of Urology, Chiba Cancer Center, 666-2 Nitona-cho, Chuo-ku, 260-8717, Chiba, Chiba, Japan aut NATIONALLICENCE 700 1- Takagi Kimiaki Prostate Center and Division of Urology, Chiba Cancer Center, 666-2 Nitona-cho, Chuo-ku, 260-8717, Chiba, Chiba, Japan aut NATIONALLICENCE 700 1- Sato Yosuke Prostate Center and Division of Urology, Chiba Cancer Center, 666-2 Nitona-cho, Chuo-ku, 260-8717, Chiba, Chiba, Japan aut NATIONALLICENCE 700 1- Akakura Koichiro Division of Urology, Japan Community Health Care Organization, Tokyo Shinjuku Medical Center, Tokyo, Japan aut NATIONALLICENCE 700 1- Ichikawa Tomohiko Department of Urology, Graduate School of Medicine, Chiba University, 1-8-1 Inohana-cho, Chuo-ku, 260-8670, Chiba, Japan aut NATIONALLICENCE 700 1- Ueda Takeshi Prostate Center and Division of Urology, Chiba Cancer Center, 666-2 Nitona-cho, Chuo-ku, 260-8717, Chiba, Chiba, Japan aut NATIONALLICENCE 773 0- International Journal of Clinical Oncology Springer Japan 20/6(2015-12-01), 1185-1191 1341-9625 20:6<1185 2015 20 10147